Zobrazeno 1 - 10 of 330 pro vyhledávání: '"Hans R Brunner"'
1
Akademický článek
Olmesartan medoxomil: current status of its use in monotherapy
Autor: Hans R Brunner
Publikováno v: Vascular Health and Risk Management, Vol Volume 2, Pp 327-340 (2006)
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 week
Externí odkaz: https://doaj.org/article/e902ff8ebefb420ea734aaf301a323d7
Zobrazit plný text záznamu
2
Akademický článek
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals
Autor: Hans R. Brunner, Kikuo Arakawa
Publikováno v: Кардиоваскулярная терапия и профилактика, Vol 10, Iss 3, Pp 22-27 (2011)
Background. For patients with hypertension, effective 24-hour blood pressure (BP) control is vital to ensure protection against the early morning surge in BP and the associated increased risk of cardiovascular events. The aim of this analysis was to
Externí odkaz: https://doaj.org/article/84fcf45f57c745749b19cff9e42fbcff
Zobrazit plný text záznamu
3
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease
Autor: Yong Huo, Martin C. Michel, Hans R. Brunner, Carolyn Foster
Publikováno v: Pharmacology & Therapeutics. 164:1-81
We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fbd5c2b294ec8ebb556b5109c23450d
https://doi.org/10.1016/j.pharmthera.2016.03.019
Zobrazit plný text záznamu
4
Dietary magnesium intake can affect mechanical properties of rat carotid artery
Autor: Alain Berthelot, Daniel Hayoz, Hans R. Brunner, Pascal Laurant
The purpose of the present study was to determine the effects of Mg deficiency and supplementation on the mechanical properties of the rat common carotid artery. The internal diameter and intra-arterial pressure of carotid artery were measured contin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df92b2f0837268bdde973ddba8c71071
http://doc.rero.ch/record/300614/files/S0007114500002129.pdf
Zobrazit plný text záznamu
5
In Vitro Effects of DuP 753, a Nonpeptide Angiotensin II Receptor Antagonist, on Human Platelets and Rat Vascular Smooth Muscle Cells
Autor: Hans R. Brunner, Eric Grouzmann, Philippe Walker, Michel Burnier, Gabriel Centeno, Bernard Waeber
These experiments were designed to assess the ability of the new nonpeptide angiotensin II antagonist DuP 753 to inhibit the binding and, particularly, to antagonize the cellular response to angiotensin II in human platelets and primary cultures of r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6bd7282aca337947b4e9ec373ce2bac
http://doc.rero.ch/record/298619/files/4-5_Pt_1-438.pdf
Zobrazit plný text záznamu
6
Cardiovascular Effects of Neuropeptide Y
Autor: Jean-François Aubert, Rolf C. Gaillard, Bernard Waeber, Jürg Nussberger, Dominique Evéquoz, Hans R. Brunner, Roger Corder
Neuropeptide Y (NPY) is present in the brain, the adrenal medulla, and peripheral sympathetic nerves. This peptide is released together with catecholamines during sympathoadrenal activation. It possesses direct vasoconstrictor properties that are not
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6695d1fed0b6c2cf12d7a34a1c9a4dba
http://doc.rero.ch/record/302914/files/1-2-193.pdf
Zobrazit plný text záznamu
7
Does protein binding modulate the effect of angiotensin II receptor antagonists?
Autor: Catherine Centeno, Hans R. Brunner, Michel Burnier, Åsa Frostell-Karlsson, Marc Maillard
Publikováno v: Journal of the Renin-Angiotensin-Aldosterone System, Vol 2 (2001)
Introduction Angiotensin II AT 1-receptor antagonists are highly bound to plasma proteins (≥ 99%). With some antagonists, such as DuP-532, the protein binding was such that no efficacy of the drug could be demonstrated clinically. Whether protein b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57aa48303660b372d29d065b0cf693a4
https://pubmed.ncbi.nlm.nih.gov/28095232
Zobrazit plný text záznamu
9
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
Autor: Steele Ronald Edward, Hans R. Brunner, Christoph Schumacher
Publikováno v: Journal of Hypertension
Context: We describe the clinical investigation of the first generation aldosterone synthase inhibitor, LCI699, in patients with essential, uncontrolled, resistant, or secondary hypertension. LCI699 competitively reduced blood pressure at lower doses
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc65c6a88cb1c8b3c64e91eae79bd434
https://doi.org/10.1097/hjh.0b013e328363570c
Zobrazit plný text záznamu
10
Cardiovascular outcomes in hypertensive patients
Autor: Anthony Schork, Michael A. Weber, Tsushung A. Hua, Yan Jia, Dion H. Zappe, Sverre E. Kjeldsen, Hans R. Brunner, Alberto Zanchetti, Gordon T. McInnes, Stevo Julius, Giuseppe Mancia
Publikováno v: Journal of Hypertension. 30:2213-2222
Objectives:To determine whether blood pressure (BP) control in hypertensive patients achieved with combination drug therapy provides the same cardiovascular benefits as with single-agent therapy.Background:Drug combinations, most often including hydr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95d90522980cb4d0f563b24ae74bc635
https://doi.org/10.1097/hjh.0b013e3283582ed6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje